Millions of Medicare Part D enrollees who once watched their prescription costs jump sharply partway through each year no longer face that mid-year spending cliff. The coverage gap, widely known as the donut hole, was formally eliminated on January 1, 2025, under the Part D redesign enacted in the Inflation Reduction Act of 2022. In its place, a $2,000 annual out-of-pocket cap now limits total beneficiary spending on covered drugs, removing the old benefit phase that had forced patients to shoulder steep cost-sharing after crossing an initial coverage threshold.
How the donut hole raised costs for Part D enrollees mid-year
Under the prior Part D benefit structure, enrollees moved through distinct spending phases each calendar year. After satisfying a deductible and passing through an initial coverage period, beneficiaries entered the coverage gap, a zone where they were responsible for a larger share of their drug costs. For years, that gap acted as a financial wall for people taking expensive maintenance medications for conditions like diabetes, cancer, or heart disease. Spending on those drugs could climb rapidly once a beneficiary crossed the initial coverage limit, and many patients responded by skipping doses or abandoning prescriptions altogether.
Congress tried to soften the blow well before the 2025 redesign. The Affordable Care Act set a schedule to close the donut hole gradually, with annual reductions targeting full closure by 2020. The Bipartisan Budget Act of 2018 accelerated part of that timeline by increasing the manufacturer discount inside the gap from 50% to 70%. Those steps reduced the sting but did not eliminate the coverage gap as a distinct benefit phase. Beneficiaries still faced higher cost-sharing once they hit the threshold, and the gap’s existence continued to shape how and whether patients filled prescriptions in the second half of each year.
What the 2025 Part D redesign actually changed
The Inflation Reduction Act, signed into law as H.R. 5376, rewrote the Part D benefit in ways that go beyond simply shrinking the gap. Starting in 2025, the redesigned benefit no longer contains an initial coverage limit or a coverage gap phase at all, according to the Congressional Research Service. Instead of moving from deductible to initial coverage to gap to catastrophic coverage, beneficiaries progress along a single continuum of spending until they hit the new annual cap.
The old Coverage Gap Discount Program, which had required drug manufacturers to provide percentage-based discounts on brand-name drugs dispensed during the gap, was replaced by a new Manufacturer Discount Program administered by CMS. Under this updated framework, pharmaceutical manufacturers enter into agreements that govern the discounts they must provide on applicable drugs throughout the benefit, rather than only inside a discrete gap phase. Part D coverage for drugs subject to the program is now available only when a manufacturer has signed a discount agreement under the new rules.
The practical result for beneficiaries is a flatter spending curve across the year. Rather than watching out-of-pocket costs spike after a few months of filling high-cost prescriptions, enrollees now accumulate spending toward a single $2,000 annual cap. Once they reach that threshold, they owe nothing more for covered Part D drugs for the rest of the year. The updated benefit structure, reflected in the Part D statute at 42 U.S.C. 1395w‑102, removes the abrupt transition that previously pushed patients into the donut hole and replaces it with a clearer, more predictable path of cost-sharing.
What the new cap means for patients and plans
For people who rely on expensive specialty drugs or multiple chronic medications, the $2,000 ceiling can represent several thousand dollars in avoided out-of-pocket spending compared with prior years. The absence of a coverage gap also simplifies decision-making: beneficiaries no longer have to track when they might cross an initial coverage limit or brace for a mid-year jump in coinsurance rates. Instead, they can focus on total spending for the year and discuss with their prescribers how best to manage therapy within that fixed exposure.
The redesign also shifts financial responsibility among Medicare, drug plans, and manufacturers. With the catastrophic phase effectively merging into the capped benefit, plans now bear a larger share of costs above the threshold than they did under the old reinsurance-heavy model. Manufacturers, in turn, provide mandated discounts under the new program across a broader span of spending, while federal reinsurance is scaled back. Policymakers intended these changes to encourage plans and manufacturers to negotiate more aggressively over prices and formulary placement, potentially improving affordability beyond the cap itself.
Still, the new structure does not erase all financial pressure. Beneficiaries with lower drug spending will not reach the cap and will continue to pay deductibles and coinsurance, and premiums could respond over time as plans adjust to their new cost-sharing obligations. Advocates and analysts will be watching closely to see whether the combination of a hard out-of-pocket limit and rebalanced liability delivers on the promise of more sustainable drug costs without undermining access to needed medications.
Free for readers: The free Retirement Shield newsletter sends plain-English help keeping more of your money in retirement — the scams to dodge, the benefits you’re owed, and what’s changing with Social Security and Medicare, a couple times a week. Get the free newsletter.
